Need a report that reflects how COVID-19 has impacted this market and its growth?
The United States diabetes devices market has been estimated to be valued at more than USD 18.9 billion by 2020, registering a CAGR of over 6% during the forecast period (2021 - 2026). Diabetes care devices are used to control glucose levels in the blood. The main types of diabetes care devices include glucose monitoring devices and management devices. Continuous glucose monitoring (CGM) devices are widely used, due to technological innovations in CGM devices. innovations like Dexcom G6 Pro that gathers real-time glucose data over a 10-day period and offers both a blinded and unblinded mode. In blinded mode, real-time glucose data is hidden from the patient and reviewed retrospectively with their healthcare professional at the end of the session. In unblinded mode, patients can see their glucose data throughout the 10-day sensor wear to gain insights and make treatment decisions in real-time. The United States is among the top five countries, with the highest diabetic population. The country has close to 100 million adults, with diabetic and pre-diabetic conditions. According to studies, diabetes is among the leading health epidemics in the country. WHO had concluded that, in 2015, diabetes was the seventh-leading cause of death in the United States.
Scope of the Report
The study provides a detailed analysis of the diabetes care devices market in the United States and includes market share, size, forecast, and industry overview.
Key Market Trends
The United States Monitoring Devices Market is Expected to Increase during the Forecast Period, with a CAGR of 5%.
In the market studied, management devices held a market share, of 26%, and it is expected to increase during the forecast period, with a CAGR of 5%. Management devices are based on insulin delivery devices, and the market is further segmented as syringes, pens, pumps, and injectors. In the United States insulin delivery devices market, the disposable pens market accounted for a high market share. Most of the patients administering insulin prefer pens over cartridges, due to their low cost. The United States is considered to be a premium market space for most of the pharmaceutical companies, as they can price their drug at a high price than the other countries and still have high sales. The country’s insurance policy, which reimburses close to 50% of the drug cost to the consumers, acts as a boon for pharmaceutical companies selling drugs or devices.
To understand key trends, Download Sample Report
Growing Diabetes and Obesity Population in the United States
The market growth of diabetic devices is directly proportional to the increasing diabetic population in the country. The diabetic population in the country has increased continuously over the past decade. Almost 24 million people are living with diabetes. Type-2 diabetes accounts for close to 95% of the diabetic population in the country. The increasing number of type-2 diabetic population has a direct correlation to the growing obesity population. In the United States, 30% of the population is living with obesity, 7.5% of those have diabetes, and this percentage is more likely to increase during the forecast period.
The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market. In 2019, the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients, ages two years and up.
In May 2021, The FDA cleared Bigfoot “Biomedical’s Unity system” (after 9 months of review). The startup plans to launch this connected pen system in the coming months following this regulatory approval, starting with a limited launch in select clinics around the United States before a broader launch.
In Aug 2021, US FDA approves Abbott’s FreeStyle Libre 2 iOS app for diabetes management. The FreeStyle Libre 2 iOS app is designed to facilitate remote monitoring, real-time alerts, and data sharing. It facilitates a complete digital offering for Abbott’s FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system.
Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Product
5.1.1 By Monitoring Devices, (Value and Volume, 2016 - 2026)
22.214.171.124 Self-monitoring Blood Glucose
126.96.36.199.1 Glucometer Devices
188.8.131.52.2 Blood Glucose Test Strips
184.108.40.206 Continuous Glucose Monitoring
5.1.2 By Management Devices, (Value and Volume, 2016 - 2026)
220.127.116.11 Insulin Pump
18.104.22.168.1 Insulin Pump Device
22.214.171.124.2 Insulin Pump Reservoir
126.96.36.199.3 Infusion Set
188.8.131.52 Insulin Syringes
184.108.40.206 Cartridges in Reusable pens
220.127.116.11 Insulin Disposable Pens
18.104.22.168 Jet Injectors
6. Market Indicators
6.1 Type-1 Diabetes Population (2016 - 2026)
6.2 Type-2 Diabetes Population (2016 - 2026)
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Becton and Dickenson
7.1.3 F. Hoffmann-La Roche AG
7.1.4 Insulet Corporation
7.1.8 Ypsomed Holding
7.1.9 Novo Nordisk
7.1.11 Eli Lilly and Company
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The United States Diabetes Devices Market market is studied from 2016 - 2027.
What is the growth rate of United States Diabetes Devices Market?
The United States Diabetes Devices Market is growing at a CAGR of >6% over the next 5 years.
What is United States Diabetes Devices Market size in 2016?
The United States Diabetes Devices Market is valued at 18 Billion USD in 2016.
What is United States Diabetes Devices Market size in 2027?
The United States Diabetes Devices Market is valued at 28 Billion USD in 2027.
Who are the key players in United States Diabetes Devices Market?
Abbott, Dexcom, Becton Dickinson, Medtronic, F. Hoffmann-La Roche AG are the major companies operating in United States Diabetes Devices Market.